Federal prosecutors have launched a criminal investigation into whether Theranos Inc. misled investors about the state of its technology and operations, according to people familiar with the matter. 
 
 Walgreens Boots Alliance Inc. and the New York State Department of Health have received subpoenas in recent weeks seeking documents and testimony about representations made to them by the Palo Alto, Calif., blood-testing company, some of the people said. 
 
 ... 

 The investigations are piling up for blood-testing startup Theranos. 
 
 The company said Monday that it's under scrutiny from the Securities and Exchange Commission and the U.S. Attorney's Office for the Northern District of California. 
 
 Those probes come on top of an ongoing inspection by the Centers for Medicare and Medicaid Services (CMS). 
 
 Theranos has positioned itself as a provider of cheaper, more efficient alternatives to traditional medical tests. It claimed it could process up to 70 lab tests on just a few drops of blood. It has been valued at more than $9 billion and billed as a classic industry disruptor. 
 
 But in October, a scathing report in the Wall Street Journal called much of its technology and testing methods into question, prompting wider scrutiny. 
 
 Theranos didn't offer much in the way of details Monday on the SEC and U.S. Attorney's Office investigations. In a company memo provided to CNNMoney, it said the probes "began following the publication of certain news articles" and "are focused on requesting documents." 
 
 Related: Theranos CEO in jeopardy after regulators propose ban 
 
 The company said it "continues to work closely with regulators and is cooperating fully with all investigations." 
 
 The SEC declined to comment on the matter. The U.S. Attorney's Office wasn't available for comment late Monday. 
 
 Theranos' disclosure of the investigations comes weeks after federal health regulators proposed banning the company's CEO, Elizabeth Holmes, from its labs. Theranos said such a move would be a "worst case scenario." 
 
 In a letter dated March 18 that was obtained by the Wall Street Journal, CMS wrote that Theranos failed to adequately address critical deficiencies at the company's California lab. Theranos said last week that it had responded and was waiting for CMS to review and respond. 
 
 The company didn't give an update Monday on the CMS inspection. 
 
 But it did say that investigations by the FDA and the Departments of Health of Pennsylvania and Arizona have been "successfully closed out." 
 
 -- Sara Ashley O'Brien contributed to this report 

 These crawls are part of an effort to archive pages as they are created and archive the pages that they refer to. That way, as the pages that are referenced are changed or taken from the web, a link to the version that was live when the page was written will be preserved.Then the Internet Archive hopes that references to these archived pages will be put in place of a link that would be otherwise be broken, or a companion link to allow people to see what was originally intended by a page's authors.The goal is to fix all broken links on the web . Crawls of supported "No More 404" sites. 

 On Theranos Inc.’s website, company founder Elizabeth Holmes holds up a tiny vial to show how the startup’s “breakthrough advancements have made it possible to quickly process the full range of laboratory tests from a few drops of blood.” 
 
 The company offers more than 240 tests, ranging from cholesterol to cancer. It claims its technology can work with just a finger prick. Investors have poured more than $400 million into Theranos, valuing it at $9 billion and her majority stake at more than half that. The 31-year-old Ms. Holmes’s...
– A success story gone sour has taken a new turn for Theranos and founder Elizabeth Holmes, with the SEC and the US attorney's office for the Northern District of California now conducting criminal investigations to determine whether the blood-testing company misled investors and others about its technologies, CNNMoney reports. Theranos has taken heat for what was once thought to be a revolutionary way of testing blood on just a finger prick, with allegations including shoddy QA procedures and a lack of response to complaints. Sources tell the Wall Street Journal that both Walgreens Boot Alliance (parent of Walgreens, which houses dozens of Theranos wellness centers) and the New York State Department of Health have received subpoenas asking for "broad information" on how Theranos represented itself while pushing its technologies and how well it was developing these technologies. The Journal has done much of the deep digging into Theranos, including an October article that detailed its troubles. Theranos provided a memo to CNN stating the latest probes started "following the publication of certain news articles" and that the company "continues to work closely with regulators and is cooperating fully." It also notes that an FDA probe and investigations by the state health departments of Arizona and Pennsylvania had been "successfully closed out." Meanwhile, Holmes appeared on the Today show Monday and said she was unaware of lacking oversight within her company, per Ars Technica. "Probably the most devastating part of this is that I thought we did [have protocols in place]," she said. She also doesn't think Theranos' flawed results put lives in danger, per the Today report.